Bal Pharma Limited (BOM:524824)
India · Delayed Price · Currency is INR 88.84
+1.23 (1.40%)
At close: Jun 18, 2026
Bal Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 62.84 | 72.15 | 73.92 | 25.72 | 56.12 |
Depreciation & Amortization | 110.79 | 71.06 | 77.77 | 72.11 | 78.52 |
Other Amortization | - | 26.65 | 22.95 | 19.18 | 11.88 |
Loss (Gain) From Sale of Assets | -0.56 | - | -0.83 | -0.3 | -12.34 |
Loss (Gain) From Sale of Investments | - | -0 | -11.8 | - | -0.06 |
Provision & Write-off of Bad Debts | 0.28 | - | 1.93 | 1.82 | 1.59 |
Other Operating Activities | 151.4 | 108.18 | 104.54 | 141.36 | 115.64 |
Change in Accounts Receivable | -19.42 | 71.49 | -149.54 | -318.93 | -96.68 |
Change in Inventory | -133.33 | -152.11 | 101.94 | -236.09 | -140.1 |
Change in Accounts Payable | 68.9 | 41.67 | -5.95 | 271.73 | 205.94 |
Change in Other Net Operating Assets | 63.53 | -35.94 | 13.13 | 8.04 | 47.46 |
Operating Cash Flow | 304.43 | 203.15 | 228.06 | -15.37 | 267.96 |
Operating Cash Flow Growth | 49.85% | -10.92% | - | - | 19.97% |
Capital Expenditures | -185.55 | -187.87 | -109.8 | -146.45 | -84.69 |
Sale of Property, Plant & Equipment | 0.56 | - | 0.12 | - | - |
Investment in Securities | 7.83 | 31.33 | -86.11 | -8.1 | -11.94 |
Other Investing Activities | -29.84 | 7.37 | 6.89 | -67.27 | 1.79 |
Investing Cash Flow | -206.99 | -149.17 | -188.91 | -221.82 | -94.85 |
Short-Term Debt Issued | 57.24 | 157.3 | 103.61 | 237.15 | - |
Long-Term Debt Issued | 34.12 | - | 58.26 | 117.02 | 30.81 |
Total Debt Issued | 91.36 | 157.3 | 161.88 | 354.17 | 30.81 |
Short-Term Debt Repaid | - | - | - | - | -93.3 |
Long-Term Debt Repaid | - | -49.49 | - | - | - |
Total Debt Repaid | - | -49.49 | - | - | -93.3 |
Net Debt Issued (Repaid) | 91.36 | 107.81 | 161.88 | 354.17 | -62.49 |
Issuance of Common Stock | - | 8.07 | 12.28 | 43.75 | - |
Common Dividends Paid | -19.11 | -19.11 | -15.69 | -15.57 | -14.82 |
Other Financing Activities | -168.12 | -175.2 | -170.53 | -141.41 | -94.91 |
Financing Cash Flow | -95.86 | -78.42 | -12.06 | 240.94 | -172.22 |
Miscellaneous Cash Flow Adjustments | -0 | 0 | - | - | - |
Net Cash Flow | 1.57 | -24.44 | 27.09 | 3.74 | 0.89 |
Free Cash Flow | 118.88 | 15.28 | 118.26 | -161.83 | 183.26 |
Free Cash Flow Growth | 677.91% | -87.08% | - | - | -3.40% |
Free Cash Flow Margin | 3.81% | 0.50% | 3.49% | -5.32% | 6.52% |
Free Cash Flow Per Share | 7.47 | 0.96 | 7.51 | -10.31 | 12.36 |
Cash Interest Paid | 168.12 | 168.54 | 163.26 | 136.83 | 104.04 |
Cash Income Tax Paid | - | 20.77 | 45.43 | 5.04 | 12.02 |
Levered Free Cash Flow | -117.38 | -144.66 | 15.36 | -234.05 | 92.28 |
Unlevered Free Cash Flow | -12.27 | -53.79 | 96.01 | -168.45 | 147.75 |
Change in Working Capital | -20.32 | -74.89 | -40.43 | -275.25 | 16.61 |